Clopidogrel is one of the most commonly used antiplatelet drugs, with indications for use in a large number of disease entities. Its various, proven in clinical trials beneficial effects resulted in the inclusion of clopidogrel into guidelines for the treatment of many diseases, including coronary heart disease and peripheral artery diseases. Nevertheless, even the most current guidelines do not cover all new references to the importance of clopidogrel in medicine. This paper aims to present the latest scientific reports on clopidogrel.Klopidogrel jest jednym z najczęściej stosowanych leków przeciwpłytkowych wskazanym do stosowania w bardzo wielu jednostkach chorobowych. Jego różnorodne, udowodnione w badaniach klinicznych, korzystne działa...
In the second half of the year 2016 two very important documents were published changing everyday pr...
Due to the common use of oral anticoagulants in the treatment of vascular diseases and their complic...
Nowadays, anticoagulant therapy is one of the most common form of medical intervention. Among others...
Clopidogrel is one of the most commonly used antiplatelet drugs, with indications for use in a large...
Podstawą wytycznych dotyczących leczenia ostrych zespołów wieńcowych (ACS) są głównie wynikidużych b...
Potent P2Y12 receptor inhibitors, i.e. prasugrel and ticagrelor, are first-line drugs in patients wi...
Jednym z leków przeciwpłytkowych stosowanych u chorych po przebytym ostrym zespole wieńcowym jest kl...
Non-vitamin K oral anticoagulants (NOAC) are drugs that relatively recently have been introduced int...
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent ...
Chronic kidney disease is regarded as one of the most significant risk factors for development of ca...
Availability of interventional treatment, effective antiplatelet and anticoagulant agents resulted i...
Hypercholesterolemia and hypertension are well recognized risk-factors ischaemic heart disease. Comb...
The need to improve the efficacy of anticoagulant therapy in secondary prevention is indicated by th...
Prasugrel i tikagrelor są doustnymi inhibitorami receptora P2Y12 wskazywanymi w wytycznych Europejsk...
In the second half of the year 2016 two very important documents were published changing everyday pr...
Due to the common use of oral anticoagulants in the treatment of vascular diseases and their complic...
Nowadays, anticoagulant therapy is one of the most common form of medical intervention. Among others...
Clopidogrel is one of the most commonly used antiplatelet drugs, with indications for use in a large...
Podstawą wytycznych dotyczących leczenia ostrych zespołów wieńcowych (ACS) są głównie wynikidużych b...
Potent P2Y12 receptor inhibitors, i.e. prasugrel and ticagrelor, are first-line drugs in patients wi...
Jednym z leków przeciwpłytkowych stosowanych u chorych po przebytym ostrym zespole wieńcowym jest kl...
Non-vitamin K oral anticoagulants (NOAC) are drugs that relatively recently have been introduced int...
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent ...
Chronic kidney disease is regarded as one of the most significant risk factors for development of ca...
Availability of interventional treatment, effective antiplatelet and anticoagulant agents resulted i...
Hypercholesterolemia and hypertension are well recognized risk-factors ischaemic heart disease. Comb...
The need to improve the efficacy of anticoagulant therapy in secondary prevention is indicated by th...
Prasugrel i tikagrelor są doustnymi inhibitorami receptora P2Y12 wskazywanymi w wytycznych Europejsk...
In the second half of the year 2016 two very important documents were published changing everyday pr...
Due to the common use of oral anticoagulants in the treatment of vascular diseases and their complic...
Nowadays, anticoagulant therapy is one of the most common form of medical intervention. Among others...